Recommendations on screening and nutritional support for patients undergoing hematopoietic stem cell transplantation (HSCT) have been presented by international nutritional societies, but nutritional practices remain poorly standardized. Following the general policy of the European Society for Blood and Marrow Transplantation (EBMT) to standardize transplantation procedures, the Complications and Quality of Life Working Party and Nursing Research Group carried out a survey among all EBMT centers about their current nutritional practices. The aim of this study was to better understand current practices, differences from available guidelines, and possible barriers for recommended nutritional therapy. Responses from 90 centers (19%) from 23 countries were received. We observed a marked variability in nutritional care between EBMT centers and a substantial lack of standardized operating procedures in screening patients for malnutrition and management of gastrointestinal GVHD. Furthermore, our study confirmed neutropenic diet as standard of care in most centers as well a preference for parenteral nutritional support over enteral. On the basis of these findings, future EBMT efforts will focus on better implementation of international nutritional guidelines into clinical practice.
Background
Low body weight before hematopoietic stem cell transplantation (HSCT) may have a severe, negative impact on transplant mortality [1, 2] and morbidity [3, 4] . Moreover, in the absence of nutritional support after HSCT, malnutrition and weight loss can occur rapidly [5] and have persistent, serious long-term effects [6] [7] [8] [9] . For these reasons, nutritional care process in the transplant setting should be dynamic, consisting of screening, assessment, development of a nutritional care plan, monitoring, and follow-up. It needs a multidisciplinary approach [10] , education, and patient/caregiver's compliance. In 2009, both the American Society for Parenteral and Enteral Nutrition (ASPEN) [11] and the European Society for Clinical Nutrition and Metabolism (ESPEN) [12] issued guidelines on nutritional support for patients undergoing HSCT. In brief, these guidelines recommend screening for malnutrition and nutritional interventions if patients are unable to maintain their nutritional status on their own. In addition, it is recommended that enteral nutrition (EN) should be the first option and preferred over parenteral nutrition (PN) due to the higher risk of side effects such as central line infections and metabolic complications. PN should be reserved for patients with severe mucositis (grade >3), ileus, or intractable vomiting. The neutropenic diet (ND) is not recommended due to the lack of evidence [13] . As there is limited evidence for all recommendations, there is broad variability of current clinical practice guidelines and many centers lack a standardized strategy for nutritional support in HSCT patients. Following the general policy of the European Society for Blood and Marrow Transplantation (EBMT) to aim at standardizing transplantation procedures, the Complications and Quality of Life Working Party and Nursing Research Group have carried out a survey among EBMT centers about their current nutritional practices. The aim of the study was to better understand differences between clinical practices and international recommendations as well as possible barriers to the use of nutritional therapy in patients undergoing HSCT. Our results could be useful for the future development of EBMT-issued recommendations toward a more standardized nutritional care process and improvement of the outcome of patients undergoing HSCT.
Materials and methods
The survey was carried out from June 2015 to January 2016 within all centers reporting to the EBMT. A questionnaire was developed by the study authors and used for data collection. The questionnaire consisted of 57 questions and focused on general measures, such as the availability of a nutritional team, standard operating procedures, implementation of nutritional interventions, dietary restrictions in terms of ND, and attitudes toward nutritional support in graftversus-host disease (GvHD). (The full questionnaire with definitions is presented in Appendix A). The reports were analyzed at the EBMT Chronic Leukemia Working Party Data Office in Leiden, The Netherlands. The forms were completed for all items in most cases, but as occasional answers were lacking (five or fewer answers to a given question unless otherwise specified), the results are usually given as frequencies of the centers answering the question.
Results

Demographics of the centers
All EBMT centers were approached (n = 469), and 90 centers (19%) from 23 countries agreed to participate. The participating centers were located in Italy (n = 34), Spain (n = 7), France (n = 6), Germany (n = 6), Turkey (n = 6), UK (n = 4), Belgium (n = 3), Poland (n = 3), Switzerland (n = 3), Australia (n = 2), Algeria (n = 2), Austria (n = 2), Hungary (n = 2), Croatia (n = 1), Czech Republic (n = 1), Denmark (n = 1), Greece (n = 1), Israel (n = 1), Lithuania (n = 1), Norway (n = 1), Russia (n = 1), Sweden (n = 1), and Tunisia (n = 1). According to the 2015 annual activity report, these centers performed a total of 3032 HSCT or 18% of total HSCT registered in the EBMT in year 2015. Characteristics of EBMT centers are depicted in Table 1 . Most of the participating centers are from the high gross national income countries (88%). The majority of centers perform 10-50 allogeneic transplants a year (57%). Furthermore, majority of the centers (60%) have >15 years of experience in performing allogeneic transplantation and majority of participating centers (56%) are JACIE accredited. Finally, most of the centers (63%) are only adultcaring centers, while all types of transplant (matched related, unrelated, haploidentical, and cord blood) are performed in 42% of participating centers (data not shown).
Standard operating procedures and team for nutritional support
Most centers (72%) have guidelines or standard operating procedures defining nutritional practice during HSCT but Cord blood 54%
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Variability of nutritional practices in peritransplant period after allogeneic...only 35% of centers have an available multidisciplinary nutritional support team including a physician, nutritionist or dietitian, nurse, and a pharmacist [14] . The remaining centers have an available dietician or nutritionist or both but a rarely available specialist nutrition nurse.
Assessment and monitoring for malnutrition Table 2 shows details of monitoring and assessment tools used in EBMT centers. Fifty-six percent of centers have available guidelines for monitoring of HSCT patients with regard to nutritional status. Consequently, the nutritional status is formally assessed in only 57% of centers before and during HSCT and in 49% of centers after discharge. The assessment is mostly made by a treating physician (65% of centers) and usually with the use of dietary history and/or anthropometric parameters. Before HSCT, 53% of centers additionally use specific nutritional indices and a minority (16%) is familiar with specific instruments as questionnaire tools as well. During inpatient stay, most of the centers (78%) also implement biochemical parameters such as albumin levels. The time and modality of nutritional counseling varies highly across the centers along the peritransplant period.
Dietary practices during HSCT
In the early post-HSCT period, most centers (93%) use either standard ND based substantially on administration of cooked foods during the neutropenic period [15] or ND with food fortification (addition of high-energy ingredients) and oral nutritional supplements (prepacked drinks or vitamin/mineral tablets). Most of the centers do not use gluten-free (80%) or lactose-free diet (60%), except in special conditions such as lactose intolerance. So long as patients are not in aplasia, most centers (66%) allow family members to bring appropriately prepared food from outside the hospital.
Nutritional support
Nutritional support among EBMT centers is usually considered in malnourished patients and in patients with unsafe oral/enteral intake. The methods of nutritional support are described in Table 3 . The most common method for "firstline" intervention is the use of oral nutritional supplements (40% of centers), followed by PN (26% of centers) and food fortification (15% of centers). Intravenous nutrition (IVN) as first-line intervention is used in 9% centers, while EN as primary intervention is used only in 4% of the centers. Oral nutritional supplements include high-energy and/or protein drinks in most (58%) of the responding centers. As many as 25% of centers use PN as prophylaxis in patients at risk of malnutrition, usually after a conditioning with myeloablative chemotherapy (in 90% of cases) or after total body irradiation-based myeloablative regimens (in 65% of cases). Most formulations used for PN are standardized preparations (60%), while the rest use individualized formulas. For IVN, most centers (56%) use all types of preparationsglucose, amino acids, and lipid solutions. Twelve centers use EN routinely as a prophylactic measure of malnutrition, usually by a nasogastric tube (in 95% of cases). Commercially available standard products are uniquely used for EN and one third of the centers use disease-specific formula as well (i.e., immune modulating, low/normal/high energy, high protein, high lipid, oligomeric/monomeric). Twentyseven percent of centers use oral immune-nutrients for the modulation of host defense mechanisms, and the most frequently used oral immune-nutrient is glutamine (in 82% of cases), followed by omega-3 acids (in 36% of the cases). Forty-three percent of the centers use PN enriched with glutamine as well.
Nutrition in gastrointestinal graft-versus-host disease
Only 56% of the centers have standardized protocols for nutritional problems in patients affected by gastrointestinal graft-versus-host disease (GI GvHD). This inevitably leads to different practices in the management of GI GvHD, a fact confirmed by this survey. In 22% of centers, oral intake is stopped if diarrhea volume exceeds 500 ml, 34% of centers stop oral intake over 1000 ml of diarrhea, 24% of centers over 1500 ml, while 19% of centers do not stop oral intake until severe pain and/or ileus develops. Similarly, introduction of PN depending on the stage of the GvHD shows great variability among the centers. However, most centers agree (70%) that patients with GI GvHD require high-calorie, high-protein, and low-fiber diet.
Discussion
Our survey is in line with similar earlier surveys that demonstrated significant variations in nutritional therapy practices in patients undergoing HSCT as well as disregard of international guidelines. These studies confirmed different nutritional practices among transplant centers in Europe [16, 17] and Asia [18] . Our survey further confirmed a marked variation of nutritional practices between EBMT centers. The most responding centers were Italian, probably due to a recent similar nutritional study performed by Italian Group for Bone Marrow Transplantation (Gruppo Italiano Trapianto Midollo Osseo; GITMO) [17] . It is well known that malnutrition negatively affects overall survival, transplant-related mortality, and relapse rates after HSCT [19, 20] . Malnutrition is a modifiable risk factor of the HSCT outcome and screening for malnutrition after HSCT has been recommended by the ASPEN and ESPEN guidelines. Despite this, only half of the centers responding to this survey routinely monitor nutrition status in patients before, during, and after HSCT. One of the potential obstacles is the lack of a consensus on the right assessment tool for malnutrition. The most frequently used anthropometrical measures and dietary history are not specific enough [21, 22] ; recent recommendations advise the use of more specific nutritional indices such as Body Mass Index [23] . However, only half of the participating centers use these specific measures, while only a minority (16%) are familiar with specifically developed nutrition assessment tools. For this reason, it seems important to direct some future EBMT efforts to educate transplant caregivers in how and when to monitor malnutrition. From our survey, it also seems that nutritional counseling in EBMT centers is a random process. This may be due to the unavailability of a "complete" nutritional support team in the majority (65%) of participating centers.
"Low microbial" or ND is still a standard of care for HSCT patients in most of the EBMT centers (93%) even though there is ongoing controversy about the risk of infections associated with food sources. Historically, the benefit of ND was based on theoretical considerations [24, 25] with no prospective trials supporting this approach, and today it is clear that the key to prevention of infections lies in safe food-handling. Moreover, some recent studies have shown higher infection rate in patients receiving ND, compared to patients whose diet included raw fruits and vegetables [26, 27] . For that reason, current EBMT Supportive care guidelines do not propose ND [28] , while American health organizations have already issued recommendations on replacing the ND with safe food-handling guidelines [29] . Cultural issues and rigidity of practices with long tradition may explain the difficulties in introducing new nutritional protocols over well-established principles in most transplant centers. No 57%
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There is also no evidence-based consensus about which parameters best define the indication for nutritional support. On the contrary, most guidelines agree that EN should be preferred over PN, except for cases of gastrointestinal failure or tube-feeding intolerance. Randomized controlled trials comparing these two approaches are lacking, but EN has been associated with better overall survival, earlier neutrophil engraftment, and lower rates of acute GvHD [30, 31] . On the other hand, PN has been associated with higher risk for infectious and metabolic complications [32, 33] . Even though the use of EN seems to be feasible [34] [35] [36] , only 4% of the participating centers in our study use it as first-line intervention for nutritional support. Moreover, 25% of centers use PN prophylactically, even though the prophylactic and routine use of PN has not been recommended [37] . Possible reasons could again lie in a traditional approach in most practices, together with logistical reasons and potential discomfort that enteral tube insertion can cause. The results of an ongoing randomized trial of the role of EN and PN in the HSCT may help to change the old paradigms in clinical practice [38] . The practical solution should be focused on the education of transplant physicians as well as on promotion of the early tube insertion before mucositis develops.
Acute GvHD represents the biggest challenge in the nutritional support of HSCT patients. Guidelines in acute GI GvHD recommend nil by mouth in patients with >500 ml of diarrhea/day (level D of evidence) and "oral upgrade diet" when introduction of oral nutrition is safe (level C). Oral upgrade diet has been proposed by the Seattle Cancer Care Alliance and consists of limited amounts of fats, fiber, lactose, acidic items, and GI irritants, which are introduced in a stepwise manner [39] . However, only one prospective study evaluated this diet in patients with GI GvHD and compared it to a historical control of patients with nil per mouth and PN [40] . There was a significantly slower decrease of serum total proteins and albumin as well as a faster recovery in the stepwise upgrade diet group. Our survey confirms highly heterogeneous practices on the cessation of oral intake in patients with GI GvHD as well as very variable indications for the start of nutritional support. These different practices are probably associated with low levels of evidence relating to available recommendations as well as with the lack of local guidelines in more than one third of participating centers. Clearly more studies are urgently needed to explore optimal nutritional strategies for this patient population.
Malnutrition can reflect the severity of chronic GvHD, not just in case of chronic GvHD of the mouth, GI tract, or lungs, but also in the case of so-called "wasting syndrome", which probably reflects the subclinical inflammation evident in GvHD [41] . Although the most crucial intervention is the treatment of GvHD itself, it is imperative to monitor these patients and consult a nutritional specialist when the weight loss becomes evident [42] . Ideally, long-term surveillance of patients with chronic GvHD for malnutrition and routine nutrition counseling should be available in all transplant centers.
Recommendations for the use of parenteral glutamine in patients undergoing HSCT are based on the early studies [43] [44] [45] [46] [47] . These studies suggested that glutamine could serve as an immune-modulator in the digestive tract by promoting intestinal healing and reducing the severity of mucositis and GvHD [48] . Today, at least a third of EBMT centers uses glutamine as an oral supplement and/or added to PN. However, more recent studies question the role of this antioxidant and other immune-nutrients [49] [50] [51] . Owing to the lack of proven benefit, the use of these substances should not be recommended anymore.
Finally, the role of healthy intestinal microbiota in the prevention of autoimmune diseases has become evident in recent years [52] [53] [54] [55] [56] . It seems that gut dysbiosis has an important role in GI GvHD, both in murine models and humans [57] [58] [59] [60] [61] . There is also an increasing evidence that intestinal microbiota modulates antitumor immunity [62] [63] [64] [65] [66] [67] . Recently, an association between the abundance of a group of bacteria in the intestinal flora with relapse and overall survival has been confirmed [68] [69] [70] . Thus the restoration of healthy microbiota with nutritional interventions could represent a novel and attractive approach for prevention and treatment of GI GvHD [71] . Moreover, this might also serve as a therapeutic target to prevent relapse and improve survival after HSCT. The role of possible interventions such as fiber-rich diet and the use of probiotics remains to be elucidated.
The major limitation of our study is the low responding rate on some of the targeted survey questions, including details on the specific measures for nutritional assessment as well as data regarding type of products used for nutritional support. In similar surveys in the future, it would be useful to add some other specific questions such as the type of secondary intervention when first-line intervention fails. In addition, data on target levels of total caloric intake, protein intake, glucose, and vitamin D level would also add valuable information useful for standardizing nutritional practices across EBMT transplant centers.
Conclusions
Based on the findings of this survey, we conclude that future EBMT initiatives should be focused on highlighting the importance of malnutrition on the HSCT outcome, better implementing specific tools for evaluation of malnutrition, and proposing the timeline for a routine nutritional follow-up as well as promoting EN over PN.
Moreover, future guidelines need to focus on replacing NDs with safe food-handling and establishing clear recommendations on the nutritional support of patients with GI GvHD. Future perspectives may also consider nutritional interventions for the restoration of healthy gut flora and prevention of GvHD.
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